Girl Planting seeds

US taxpayers paid for remdesivir’s development, so why will Gilead get all the profit?

To make progress with remdesivir, the drug that’s buoyed expectations for the treatment of the Wuhan coronavirus (COVID-19), Gilead Sciences needed help from American taxpayers, getting assistance from three federal health agencies. Despite this, the federal agencies have not asserted patent rights to the drug, meaning that Gilead will have little constraint when it sets a price for the drug in the coming weeks. Remdesivir originally started out as a reject, an also-ran in a search for anti-viral drugs. The drug’s path to relevance did not begin until Robert Jordan, a Gilead scientist at the time, looked at it as part of a side project.  Read more.....

 

Back

 
 
close (X)